Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.
about
Nucleoside binding site of herpes simplex type 1 thymidine kinase analyzed by X-ray crystallographyThe effect of substrate binding on the conformation and structural stability of Herpes simplex virus type 1 thymidine kinaseImproving nucleoside diphosphate kinase for antiviral nucleotide analogs activationBacterial Cytosine Deaminase Mutants Created by Molecular Engineering Show Improved 5-Fluorocytosine-Mediated Cell Killing In vitro and In vivoExploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligandsStructure to 1.9 A resolution of a complex with herpes simplex virus type-1 thymidine kinase of a novel, non-substrate inhibitor: X-ray crystallographic comparison with binding of aciclovirBiochemical and structural characterization of (South)-methanocarbathymidine that specifically inhibits growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cellsNovel therapeutic approaches for various cancer types using a modified sleeping beauty-based gene delivery systemA mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography.Improving enzymes for cancer gene therapy.Applied molecular evolution of O6-benzylguanine-resistant DNA alkyltransferases in human hematopoietic cellsEnhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.Molecular and functional imaging technology for the development of efficient treatment strategies for gliomas.A rapid and sensitive method for the quantification of ganciclovir in plasma using liquid chromatography/selected reaction monitoring/mass spectrometry.DNA polymerase active site is highly mutable: evolutionary consequences.Assembly of designed oligonucleotides as an efficient method for gene recombination: a new tool in directed evolution.Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.Switching on the lights for gene therapyFusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo.Neural stem cell therapy for cancer.In situ use of suicide genes for therapy of brain tumours.Microglial Activation in Traumatic Brain Injury.Prodrug-activating systems in suicide gene therapy.Prodrug activation enzymes in cancer gene therapy.Imaging transgene expression with radionuclide imaging technologiesPET imaging of heat-inducible suicide gene expression in mice bearing head and neck squamous cell carcinoma xenograftsNoninvasive imaging of protein-protein interactions in living animalsPositron-emission tomography reporter gene expression imaging in rat myocardium.Semiautomated radiosynthesis and biological evaluation of [18F]FEAU: a novel PET imaging agent for HSV1-tk/sr39tk reporter gene expressionPlant thymidine kinase 1: a novel efficient suicide gene for malignant glioma therapyGene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice.Early stem cell engraftment predicts late cardiac functional recovery: preclinical insights from molecular imaging.Suicide genes: monitoring cells in patients with a safety switch.A nucleoside kinase as a dual selector for genetic switches and circuits.Discovery of superior enzymes by directed molecular evolution.Assessing directed evolution methods for the generation of biosynthetic enzymes with potential in drug biosynthesis.Orthology between the genomes of Plasmodium falciparum and rodent malaria parasites: possible practical applications.Transcriptionally targeted gene therapy to detect and treat cancer.Gene therapy strategies to improve the effectiveness of cancer radiotherapy.
P2860
Q27627766-8CAAED85-B716-49A8-9D86-625CA59671B3Q27630791-9F99F65E-395A-46DE-9F72-E54A57493F66Q27639483-981C8CF1-5018-4346-B448-ACCD1EC5437DQ27655704-0A2B39EB-153E-49CD-9009-F04ADB163311Q27765161-67870B45-B7C3-4951-A65C-F8EBD3FECFD0Q27766894-D43867A8-55A6-43B5-80CF-987E0FD69D58Q28263579-F66B0110-4CE0-419E-9B39-D88550C5AB58Q28660424-573F8179-5A16-492F-9068-D727B74C6662Q30647460-BD998195-FD32-4C62-B3AE-A4245252AAB0Q30650758-967B2DC1-CF75-4C6C-94B5-A884E51EFA00Q30663736-E2F39543-89AA-4FFD-BDDF-BF5ED510767DQ30761595-888A3CC4-CEB9-4832-9719-1F0F12AAF0FFQ30775012-BA6E3CA0-83D5-4128-A9D0-BEE852B178D1Q30842651-D64A76FD-78AC-45EC-8DCD-3749A520B8D6Q30869765-8A150A68-5B0F-4BC9-B656-029910664D19Q31123994-44DF9780-F5AA-4E50-B433-721490CF6E64Q33184179-7752DBC8-8569-4BE7-A2DF-D8A7A212361EQ33287475-50F09F2D-2B79-4F41-A1AB-D4AB047005ECQ33598652-3E1C0862-52D0-49FB-B1BD-796109CB7D2FQ33704489-C4EB5011-9D8B-4D4E-A4C2-A8B514C8E823Q33841658-E040FEBB-88FE-4BA0-B7BE-68C02A9FDF88Q33843373-A04EA539-1CA3-4C81-B2AC-BCD560D0C360Q33904264-F519739D-8631-4F61-8D54-6125A62771BCQ33968115-1ED4FDD8-D4EF-4CF2-B81E-1EBA7FA60FA7Q33995799-D4CAFAAA-99ED-4E56-A9F9-5EC0E92F0BD6Q34018755-F7FBC0AC-C02D-4A7D-9726-A60C525191D3Q34068030-45D31E62-5348-4932-B939-7E15D9DC2204Q34077922-D2B53C6F-87B4-40AE-9773-33CAE70CA389Q34077927-1150C132-04E2-447B-A432-ED0BAB61DBE5Q34132910-8D00ED9F-7719-4FE5-A14A-AF5C6B62DBD5Q34176439-87E72A58-3886-455A-9F26-92C380F8CFC6Q34204696-02C5C6E1-688C-4B8F-BFAB-34A37BEDCAF6Q34260802-416FEADF-2FC6-47E7-AD96-BFFFFDF86B6BQ34462056-4CD9E1EB-8F80-4B97-9847-BFB59507C1B2Q34559519-7767BC0A-A160-4F6C-944F-7B2C4E0F2EB8Q34596533-FF8452CB-7745-404B-BAE8-F9BEB750F44FQ35161643-3AA47F22-C4CC-4C87-9837-EA7BDB9AE847Q35212991-16E00F47-9956-4938-8114-35E54DD2E69AQ35558678-F2595381-0337-428C-8BBF-1779F17C4ABBQ35925611-05432E9D-DE50-4CA3-921D-B163D7935581
P2860
Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Creation of drug-specific herp ...... nase mutants for gene therapy.
@en
Creation of drug-specific herp ...... nase mutants for gene therapy.
@nl
type
label
Creation of drug-specific herp ...... nase mutants for gene therapy.
@en
Creation of drug-specific herp ...... nase mutants for gene therapy.
@nl
prefLabel
Creation of drug-specific herp ...... nase mutants for gene therapy.
@en
Creation of drug-specific herp ...... nase mutants for gene therapy.
@nl
P2093
P2860
P356
P1476
Creation of drug-specific herp ...... nase mutants for gene therapy.
@en
P2093
P2860
P304
P356
10.1073/PNAS.93.8.3525
P407
P577
1996-04-01T00:00:00Z